AIVITA Biomedical, Inc. products

AIVITA’s immunotherapy technology creates personalized vaccines for cancer patients that target and eliminate tumor-initiating cells which are the seed of the disease. Used alone or in parallel with other treatments, AIVITA’s cancer immunotherapy represents a powerful new approach in the search for curative treatments for cancer.

AIVITA Biomedical is using its patient-specific vaccine platform to develop a rapidly scalable vaccine candidate, AV-COVID-19, for the novel coronavirus (SARS-CoV-2). AIVITA’s personalized vaccine begins with a basic blood draw, from which the recipient’s own immune cells are extracted and loaded with SARS-CoV-2 antigen. The resulting personalized treatment is designed to create adaptive immunity against COVID-19. AIVITA’s patient-specific vaccine platform has been used to create treatments for multiple areas of cancer, with promising safety and efficacy reported to date.